CAR T cells

The FOXO1 transcription factor boosts T cells’ memory and reduces dysfunction.

Multi-targeted Cas13 screens help researchers avoid permanent DNA cuts and evade T cell exhaustion.

Living drugs get a boost from emerging engineering strategies that focus on safety and specificity.

From smart receptors to novel biologics, scientists plan to overcome the challenges of treating solid tumors.

Christopher Klebanoff hopes that his search for a small fraction of cancer-specific antigens will have a big impact on cancer cell therapies.

A CRISPR-based screening platform helped scientists identify a transcription factor that makes CAR T cells better at killing cancer cells. 

Bioengineered bacteria sneak past solid tumor defenses to guide CAR T cells’ attacks.

This year’s Breakthrough Prizes honor advances in CAR T cancer therapies, cystic fibrosis, and Parkinson’s disease.

Two studies in mice now show that researchers can control when and where CAR T cells are active, potentially overcoming previous hurdles for CAR T–based treatments.

Researchers found that naturally-occurring CD7-negative T cells avoid self-destruction and are good effectors in CAR T therapy for T cell blood cancers.

Researchers determined the safety and antitumor ability of genetically engineered CAR T cells that circumvent immune suppression in a prostate cancer phase I clinical trial.

First, the genetically engineered cells became CD8⁺ killer T cells that wiped out his leukemia. Then they transformed into a stable population of CD4⁺ helper T cells that continue to circulate in his body.

Specialized immune cells generated in vivo reduce cardiac scar tissue in mice, a new study shows.